Beta Bionics, Inc.

We are pursuing a multi-channel coverage and reimbursement strategy designed to maximize access to the iLet across the T1D population and provide PWD greater flexibility and affordability in selecting their insulin delivery system. Historically, most insulin pumps have been reimbursed through the durable medical equipment (DME) channel, which continues to cover the iLet for a growing portion of payors. Under this model, patients typically make a significant upfront payment and are eligible for device replacement only after the standard four-year warranty period. While this structure ensures predictable reimbursement for payors, it can create financial and timing barriers that limit adoption of new and more effective technologies.

To expand access beyond the DME coverage, we are working with commercial and government payors to increase availability of the iLet through the pharmacy benefit plan (PBP) channel, which follows a “pay-as-you-go” model. This structure removes large upfront costs and allows more rapid adoption of new innovations, while providing payors the opportunity to capture longer-term healthcare savings through improved disease management and reduced complications. We believe this dual-channel approach improves accessibility for PWD, enhances flexibility for healthcare providers, and increases overall market penetration of the iLet, while positioning us to generate more consistent recurring revenue over the expected life cycle of the device.